News and Announcements
Dragonfly Biosciences ASX Listing Applications are now open
- Published December 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Finexia is pleased to advise that the Dragonfly Biosciences initial public offer (IPO) is now open and accepting applications from the public. The company is seeking raise A$10M with the aim of listing on the ASX in late December 2021.
Dragonfly Biosciences Ltd is a vertically integrated ‘seed-to-shelf’ cannabidiol (CBD) business that trades under the Dragonfly CBD brand. The Company owns the entire value chain from their certified organic farms, extraction facilities and state of the art laboratories used for producing premium CBD products.
Dragonfly CBD products have been voted “Best CBD Product” in 2020 by Boots UK, one of the world’s most respected health and beauty retailer and pharmacy chains. Dragonfly’s product distribution extends into national grocery and specialty chains including Tesco, Sanisbury’s and Amazon UK, securing their status as a market leader in the UK and beyond.
The Company is issuing 50M shares at A$0.20 through the IPO and intends to raise A$10M to be deployed for accelerated global expansion and further product development.
Applications close 5.00pm AEST 14 December 2021.
To be part of the exciting journey that is Dragonfly, please obtain a copy of the prospectus via the button below.
Download Replacement Prospectus
About the Company
Dragonfly Biosciences was incorporated on 29 June 2017 and is a premium retailer of cannabidiol (CBD) oil. Through its extensive research and development, Dragonfly controls the process from seed to sale, with the aim of producing the highest and most consistent product quality. Dragonfly currently offers a range of CBD health and lifestyle products.
Dragonfly aims to expand its business and product range in line with legislative changes in Europe, the USA and Australia. As demand grows for CBD health supplements, Dragonfly seeks to be the go-to producer and supplier of CBD for both businesses and consumers.
Dragonfly’s products are tested in third-party laboratories, as well as implementing its own testing regime to ensure consistency and quality across the board with Good Manufacturing Practices (GMP). Its product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
